Article Information
- Received January 9, 2024
- Revision received April 12, 2024
- Accepted April 17, 2024
- First published April 25, 2024.
- Version of record published June 26, 2024.
Author Information
Author contributions
Author contributions: D.A.F., D.G.S., and K.L.E.J. designed research; D.A.F., H.d.A.O., J.C., R.M.C., and K.L.E.J. performed research; D.A.F., H.d.A.O., J.C., and K.L.E.J. analyzed data; D.A.F. wrote the paper.
Disclosures
- Received January 9, 2024.
- Revision received April 12, 2024.
- Accepted April 17, 2024.
We thank the University of Alabama at Birmingham (UAB) Flow Cytometry and Single-Cell Core Facility, particularly Dr. Shanrun Liu and Dr. Vidya Sagar Hanumanthu, for their assistance in protocol development, and Dr. Jeremy Day (UAB Comprehensive Neuroscience Center) and Dr. Ashley Harms (UAB Center for Neurodegeneration and Experimental Therapeutics), for their guidance in method development and interpretation. This work was supported by grants from the American Parkinson Disease Association and the Parkinson Association of Alabama to K.L.E.J., as well as the APDA Advanced Center for Parkinson Research at UAB.
D.G.S. has served as a consultant for or received honoraria from AbbVie, Curium Pharma, ApPello, Theravance, Sanofi-Aventis, Alnylam Pharmaceuticals, Coave Therapeutics, BlueRock Therapeutics, Biohaven, Eli Lilly, and F. Hoffmann-La Roche. All remaining authors declare no competing interests.
- Correspondence should be addressed to Karen L. Eskow Jaunarajs at karenej{at}uab.edu.
Funding
American Parkinson Disease Assocaition
Parkinson Association of Alabama
Other Version
- previous version (April 25, 2024).
- You are viewing the most recent version of this article.
